Japan Approves Eisai-Biogen LEQEMBI Pen, Opening Path to At-Home Alzheimer’s Dosing

Japan has approved LEQEMBI Pen, a subcutaneous autoinjector version of Eisai and Biogen’s Alzheimer’s drug lecanemab, adding a once-weekly 500 mg dosing option for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The approval creates a path to home administration, but Japanese patients will not be able to begin self-injecting immediately because a separate health-system listing step must still be completed.

The new formulation changes how LEQEMBI can be delivered rather than expanding the treatment population. The approved dose is 500 mg once a week, given as two 250 mg injections, compared with the existing intravenous regimen administered every two weeks in a medical setting.

In their September 16 announcement, Eisai and Biogen said each pen injection takes about 15 seconds and may be administered by a care partner or by the patient after the required conditions for self-administration are met. The companies said the pen is intended to reduce time spent receiving therapy and lessen reliance on infusion capacity, though patients will still need clinical oversight and MRI monitoring for amyloid-related imaging abnormalities.

At-home use still requires an additional Japanese listing step

Japan’s Ministry of Health, Labour and Welfare confirmed the regulatory action in an official September 16 approval notice, which lists LEQEMBI 250 mg Pen with Eisai as the applicant. The notice establishes the approval itself, while the companies provided additional detail on when self-administration can begin under Japan’s health-insurance framework.

According to Eisai and Biogen, at-home self-administration will become possible only after LEQEMBI Pen is added to an injectable-drug list designated by the health minister following deliberation and approval by the Central Social Insurance Medical Council. The companies said that step is expected, in principle, within 60 days of the drug approval.

Even after that listing, the first administration is not designed to move straight into the home. Treatment initiation must take place by a physician or under a physician’s direct supervision at a medical facility, and doctors must decide whether self-administration is appropriate for the individual patient.

Patients, family members or caregivers who will give the injections must receive education and training, understand the risks associated with the medicine and how to respond to them, and demonstrate that they can reliably administer the drug. Those conditions make the at-home label more flexible than an infusion-only regimen, but they also preserve a medical gate around who can use the pen outside a clinic.

MRI monitoring also remains part of treatment. The companies said brain imaging is performed before treatment starts and again at specified points after initiation, as with intravenous LEQEMBI, because the therapy can be associated with amyloid-related imaging abnormalities, or ARIA.

The pen changes delivery, not LEQEMBI’s approved Japanese indication

LEQEMBI Pen is approved for slowing the progression of mild cognitive impairment and mild dementia due to Alzheimer’s disease, the same early-stage population for which intravenous lecanemab was approved in Japan in September 2023. Lecanemab is a monoclonal antibody directed at aggregated forms of amyloid beta, including soluble protofibrils and insoluble fibrils found in amyloid plaques.

The Japanese pen approval was based on the 18-month core portion of the Phase 3 Clarity AD study together with subcutaneous-administration studies from the longer-term extension program and associated modeling and simulation. Eisai and Biogen said once-weekly 500 mg subcutaneous dosing produced exposure similar to the every-two-week IV regimen and supported their expectation of comparable efficacy.

That distinction matters because the approval announcement does not describe a new head-to-head efficacy trial showing that the pen is clinically superior to IV treatment. The companies are relying on exposure matching, clinical and biomarker information from the development program, and regulatory modeling to support the new route of administration.

The companies described the overall safety profile of subcutaneous dosing as generally similar to IV use. They also reported a 1.4% rate of systemic injection or infusion-related reactions in participants newly initiated on subcutaneous lecanemab, but that figure came from clinical data using a once-weekly 720 mg vial formulation rather than the newly approved 500 mg pen regimen, so it should not be read as a direct event rate for the commercial pen dose.

Japan becomes the third market to approve subcutaneous initiation dosing

Eisai and Biogen said Japan is the third country to approve a subcutaneous LEQEMBI formulation. The United States approved LEQEMBI IQLIK for subcutaneous maintenance dosing in August 2025 and expanded it to initiation dosing in July 2026, while China approved subcutaneous initiation treatment earlier in September 2026.

The Japanese approval therefore extends a broader shift in LEQEMBI’s delivery options from infusion-center treatment toward a regimen that can move part of administration into the home. The practical effect in Japan will depend on the additional MHLW-designated injectable-drug listing, physician assessment, training requirements and continued safety monitoring rather than on the marketing authorization alone.

For Eisai and Biogen, the pen also addresses a logistical constraint around chronic anti-amyloid therapy: repeated infusion appointments consume patient time and clinic resources. A home-capable autoinjector can reduce that burden for suitable patients, although it does not eliminate specialist involvement, imaging requirements or the need to manage treatment risks.

Eisai leads lecanemab’s global development and regulatory submissions, while the two companies co-commercialize and co-promote the drug. The next concrete milestone in Japan is the health-system decision needed to place LEQEMBI Pen on the designated injectable-drug list, the step the companies say should generally occur within 60 days of approval before at-home self-administration can begin.